A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–19. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatol. 2018;68(2):723–750. doi:10.1002/hep.29913.
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2362–2368. doi:10.1158/1055-9965.EPI-11-0643.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatol. 2011;54(2):562–572. doi:10.1002/hep.24423.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterol. 2011;141(4):1220–1230. doi:10.1053/j.gastro.2011.06.063.
   PubMed Web of Science ®Google Scholar
• Yang SF, Huang HD, Fan WL, Jong YJ, Chen MK, Huang CN, Chuang CY, Kuo YL, Chung WH, Su SC et al. Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer. Oral Oncol. 2018;77:1–8. doi:10.1016/j.oraloncology.2017.12.005.
   PubMed Web of Science ®Google Scholar
• Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S, Kiguchi Y, Yasuma K, Watanabe E, Tanoue T, et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Sci. 2017;358(6361):359–365. doi:10.1126/science.aan4526.
   PubMed Web of Science ®Google Scholar
• Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier E, Yao J, Wu L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64. doi:10.1038/nature13568.
   PubMed Web of Science ®Google Scholar
• Lu H, Ren Z, Li A, Zhang H, Jiang J, Xu S, Luo Q, Zhou K, Sun X, Zheng S, Li L. Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep. 2016;6(1):33142. doi:10.1038/srep33142.
   PubMedGoogle Scholar
• Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68(6):1014–1023. doi:10.1136/gutjnl-2017-315084.
   PubMed Web of Science ®Google Scholar
• Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, et al. The human tumor microbiome is composed of tumor type–specific intracellular bacteria. Sci. 2020;368(6494):973–980. doi:10.1126/science.aay9189.
   PubMed Web of Science ®Google Scholar
• Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Sci. 2017;357(6356):1156–1160. doi:10.1126/science.aah5043.
   PubMed Web of Science ®Google Scholar
• Komiyama S, Yamada T, Takemura N, Kokudo N, Hase K, Kawamura YI. Profiling of tumour-associated microbiota in human hepatocellular carcinoma. Sci Rep. 2021;11(1):10589. doi:10.1038/s41598-021-89963-1.
   PubMed Web of Science ®Google Scholar
• Logue JB, Stedmon CA, Kellerman AM, Nielsen NJ, Andersson AF, Laudon H, Lindström ES, Kritzberg ES. Experimental insights into the importance of aquatic bacterial community composition to the degradation of dissolved organic matter. Isme J. 2016;10(3):533–545. doi:10.1038/ismej.2015.131.
   PubMed Web of Science ®Google Scholar
• Treangen TJ, Koren S, Sommer DD, Liu B, Astrovskaya I, Ondov B, Darling AE, Phillippy AM, Pop M. MetAMOS: a modular and open source metagenomic assembly and analysis pipeline. Genome Biol. 2013;14(1):R2. doi:10.1186/gb-2013-14-1-r2.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457–62. doi:10.1093/nar/gkv1070.
   PubMed Web of Science ®Google Scholar
• Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformat. 2014;30:3123–3124. doi:10.1093/bioinformatics/btu494.
   Google Scholar
• Friedman J, Alm EJ. Inferring correlation networks from genomic survey data. PLoS Comput Biol. 2012;8(9):e1002687. doi:10.1371/journal.pcbi.1002687.
   PubMed Web of Science ®Google Scholar
• Gao L, Xu T, Huang G, Jiang S, Gu Y, Chen F. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell. 2018;9(5):488–500. doi:10.1007/s13238-018-0548-1.
   PubMed Web of Science ®Google Scholar
• Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH, Yu J. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after helicobacter pylori eradication. Gut. 2020;69(9):1572–1580. doi:10.1136/gutjnl-2019-319826.
   PubMed Web of Science ®Google Scholar
• Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, Li X, Ma Y. Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nat Commun. 2021;12(1):6757. doi:10.1038/s41467-021-27112-y.
   PubMed Web of Science ®Google Scholar
• Fuzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteom. 2013;10(1):13. doi:10.1186/1559-0275-10-13.
   PubMed Web of Science ®Google Scholar
• Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2. doi:10.1172/jci.insight.94416.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatol. 2015;62(4):1260–1271. doi:10.1002/hep.27819.
   PubMed Web of Science ®Google Scholar
• Kartal E, Schmidt TSB, Molina-Montes E, Rodriguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alhamwe BA, Alves RJ, Carrato A, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022;71(7):1359–1372. doi:10.1136/gutjnl-2021-324755.
   PubMed Web of Science ®Google Scholar
• Flemer B, Warren RD, Barrett MP, Cisek K, Das A, Jeffery IB, Hurley E, O‘riordain M, Shanahan F, O‘toole PW. The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 2018;67(8):1454–1463. doi:10.1136/gutjnl-2017-314814.
   PubMed Web of Science ®Google Scholar
• Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, et al. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis. 2018;67(6):869–877. doi:10.1093/cid/ciy205.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang D, Qiao S, Wu X, Cao S, Wang L, Su X, Li L. Metabolic and microbial signatures in rat hepatocellular carcinoma treated with caffeic acid and chlorogenic acid. Sci Rep. 2017;7(1):4508. doi:10.1038/s41598-017-04888-y.
   PubMedGoogle Scholar
• Ponziani FR, De Luca A, Picca A, Marzetti E, Petito V, Del Chierico F, Reddel S, Paroni Sterbini F, Sanguinetti M, Putignani L, Gasbarrini A Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma. Hepatol Commun. 2022;6(6):1492–1501. doi:10.1002/hep4.1905.
   PubMed Web of Science ®Google Scholar
• Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang YX, Chan AWH, Wei H, Yang X, Sung JJY, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761–774. doi:10.1136/gutjnl-2019-319664.
   PubMed Web of Science ®Google Scholar
• Byndloss MX. Microbial management. Science. 2020;369:153. doi:10.1126/science.abc5619.
   PubMed Web of Science ®Google Scholar
• Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk. J Clin Med. 2020;9(8):2648. doi:10.3390/jcm9082648.
   PubMed Web of Science ®Google Scholar
• Aymeric L, Donnadieu F, Mulet C, du Merle L, Nigro G, Saffarian A, Bérard M, Poyart C, Robine S, Regnault B, et al. Colorectal cancer specific conditions promote streptococcus gallolyticus gut colonization. Proceedings of the National Academy of Sciences of the United States of America; 2018; 115:E283–91.
   Google Scholar
• Yang N, Xu J, Wang X, Chen N, Su L, Liu Y. The spatial landscape of the bacterial community and bile acids in the digestive tract of patients with bile reflux. Front Microbiol. 2022;13:835310. doi:10.3389/fmicb.2022.835310.
   PubMedGoogle Scholar
• Yan H, Wei W, Hu L, Zhang Y, Zhang H, Liu J. Reduced feeding frequency improves feed efficiency associated with altered fecal microbiota and bile acid composition in pigs. Front Microbiol. 2021;12:761210. doi:10.3389/fmicb.2021.761210.
   PubMedGoogle Scholar
• Louis P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA: acetate CoA-transferase gene. Environ Microbiol. 2010;12(2):304–314. doi:10.1111/j.1462-2920.2009.02066.x.
   PubMed Web of Science ®Google Scholar
• Missiaen R, Anderson NM, Kim LC, Nance B, Burrows M, Skuli N, Carens M, Riscal R, Steensels A, Li F, et al. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 2022;34(8):1151–67 e7. doi:10.1016/j.cmet.2022.06.010.
   PubMed Web of Science ®Google Scholar
• Ding Z, Ericksen RE, Escande-Beillard N, Lee QY, Loh A, Denil S, Steckel M, Haegebarth A, Wai Ho TS, Chow P, et al. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J Hepatol. 2020;72(4):725–735. doi:10.1016/j.jhep.2019.10.026.
   PubMed Web of Science ®Google Scholar
• De Falco P, Lazzarino G, Felice F, Desideri E, Castelli S, Salvatori I, Ciccarone F, Ciriolo MR. Hindering NAT8L expression in hepatocellular carcinoma increases cytosolic aspartate delivery that fosters pentose phosphate pathway and purine biosynthesis promoting cell proliferation. Redox Biol. 2023;59:102585. doi:10.1016/j.redox.2022.102585.
   PubMed Web of Science ®Google Scholar
• Hu X, He Y, Han Z, Liu W, Liu D, Zhang X, Chen L, Qi L, Chen L, Luo Y, et al. PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma. Cell Death Dis. 2022;13(11):1010. doi:10.1038/s41419-022-05448-7.
   PubMed Web of Science ®Google Scholar
• Li JT, Yang H, Lei MZ, Zhu WP, Su Y, Li KY, Zhu WY, Wang J, Zhang L, Qu J, et al. Dietary folate drives methionine metabolism to promote cancer development by stabilizing MAT IIA. Signal Transduct Target Ther. 2022;7:192.
   PubMed Web of Science ®Google Scholar
• Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, Hu Y, Song B, Jiang Z, Ge Z, et al. Gut akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes. 2021;13(1):1–19. doi:10.1080/19490976.2021.1927633.
   PubMed Web of Science ®Google Scholar
• Ram AK, Vairappan B, Srinivas BH. Nimbolide attenuates gut dysbiosis and prevents bacterial translocation by improving intestinal barrier integrity and ameliorating inflammation in hepatocellular carcinoma. Phytother Res. 2022;36(5):2143–2160. doi:10.1002/ptr.7434.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y, Liu X. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019;11(1):1. doi:10.1186/s13099-018-0281-6.
   PubMedGoogle Scholar
• Plaza-Diaz J, Solis-Urra P, Rodriguez-Rodriguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadia-Molina F, Álvarez-Mercado AI. The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage. Int J Mol Sci. 2020;21(21):21. doi:10.3390/ijms21218351.
   Web of Science ®Google Scholar
• Huang H, Ren Z, Gao X, Hu X, Zhou Y, Jiang J, Lu H, Yin S, Ji J, Zhou L, et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med. 2020;12(1):102. doi:10.1186/s13073-020-00796-5.
   PubMed Web of Science ®Google Scholar
• Chng KR, Chan SH, Ng AHQ, Li C, Jusakul A, Bertrand D, Wilm A, Choo SP, Tan DMY, Lim KH, et al. Tissue microbiome profiling identifies an enrichment of specific enteric bacteria in opisthorchis viverrini associated cholangiocarcinoma. EBioMedicine. 2016;8:195–202. doi:10.1016/j.ebiom.2016.04.034.
   PubMed Web of Science ®Google Scholar
• Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178(4):795–806 e12. doi:10.1016/j.cell.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Garrett WS. Cancer and the microbiota. Science. 2015;348:80–86. doi:10.1126/science.aaa4972.
   PubMed Web of Science ®Google Scholar
• Dzutsev A, Badger JH, Perez-Chanona E, Roy S, Salcedo R, Smith CK, Trinchieri G. Microbes and cancer. Annu Rev Immunol. 2017;35(1):199–228. doi:10.1146/annurev-immunol-051116-052133.
   PubMedGoogle Scholar
• Ramirez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, Gálvez EM. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. Trends Cancer. 2020;6(2):86–97. doi:10.1016/j.trecan.2019.12.007.
   PubMed Web of Science ®Google Scholar
• Fu A, Yao B, Dong T, Chen Y, Yao J, Liu Y, Li H, Bai H, Liu X, Zhang Y, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022;185(8):1356–72 e26. doi:10.1016/j.cell.2022.02.027.
   PubMed Web of Science ®Google Scholar
• Knippel RJ, Drewes JL, Sears CL. The cancer microbiome: recent highlights and knowledge gaps. Cancer Discov. 2021;11(10):2378–2395. doi:10.1158/2159-8290.CD-21-0324.
   PubMed Web of Science ®Google Scholar
• Jia W, Rajani C, Xu H, Zheng X. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma. Protein Cell. 2021;12(5):374–393. doi:10.1007/s13238-020-00748-0.
   PubMed Web of Science ®Google Scholar
• Clooney AG, Eckenberger J, Laserna-Mendieta E, Sexton KA, Bernstein MT, Vagianos K, Sargent M, Ryan FJ, Moran C, Sheehan D, et al. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut. 2021;70(3):499–510. doi:10.1136/gutjnl-2020-321106.
   PubMed Web of Science ®Google Scholar
• Stewart CJ, Ajami NJ, O’Brien JL, Hutchinson DS, Smith DP, Wong MC, Ross MC, Lloyd RE, Doddapaneni H, Metcalf GA, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature. 2018;562(7728):583–588. doi:10.1038/s41586-018-0617-x.
   PubMed Web of Science ®Google Scholar
• Lin H, Peddada SD. Analysis of compositions of microbiomes with bias correction. Nat Commun. 2020;11:3514. doi:10.1038/s41467-020-17041-7.
   PubMed Web of Science ®Google Scholar
• Zhou H, He K, Chen J, Zhang X. LinDA: linear models for differential abundance analysis of microbiome compositional data. Genome Biol. 2022;23(1):95. doi:10.1186/s13059-022-02655-5.
   PubMed Web of Science ®Google Scholar
• Hu Y, Satten GA, Hu YJ. LOCOM: a logistic regression model for testing differential abundance in compositional microbiome data with false discovery rate control. Proceedings of the National Academy of Sciences of the United States of America. 2022; 119:e2122788119.
   Google Scholar